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Poster Session I 75Results: Patients have had a median of 10 to 124 ECP treat-
ments. The median number of treatments that enabled initial
ECP schedule taper was 22(10–124) and to achieve a CR was 62
treatments. Objective response was achieved 61% of patients (CR
in 2 patients at 8 and 15 months; PR in 6 patients). Fifteen percent
had stable disease and 23% progressed. At the time of this report 6
patients are still receiving ECP. Refer to table for organ-specific re-
sponse. Of note, six of 10 patients with lichenoid GVHD and 3 of 4
with sclerotic GVHD improved. Nine patients have been able to ta-
per corticosteroids$50% from starting dose. Five patients have
died (3 with progressive GVHD, 2 with infection/GVHD).
ECP is an alternative effective method to treat moderate to severe
SR cGVHD in pediatric patients. ECP has allowed for significant
corticosteroid sparing. Prospective studies are necessary to deter-
mine optimal schedule and durability of response.
Response by Organ
System Manifestation N CR PR SD PDSkin Rash/Lichenoid 10 2 4 4 -
Fasciitis/Scleroderma 4 1 2 1 -Oral Symptoms/
lichenoid/erythema9 2 7 - -Ocular Symptoms/need
for treatment3 1 1 1 -Joints Arthralgias/
Contractures5 2 1 2 -GI Vomiting/Abdominal
Pain/Diarrhea3 - 1 2 -Liver Bilirubin . 2 8 1 2 3 2
Pulmonary Worsening
symptoms/PFTs
4 - 1 2 1202
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Survival following AlloSCT for HR AML ($CR3, induction fail-
ure [IF], refractory disease) is dismal (#10%). BuCy is standard
conditioning in children with good risk AML (Woods et al, Blood,
2001). CD33 is expressed in 80–90% of childhood AML (Creutzig
et al, Blood, 1997). GO, an anti-CD33 immunotoxin, induces re-
mission in 20–30% of relapsed/refractory childhood AML (Arceci
et al, Blood, 2005). We have reported the safety of GO as post-con-
solidation therapy after reduced intensity conditioning alloSCT in
good risk childhood AML (Roman et al, Clin Can Res, 2005). In
this study, we explore the feasibility and safety of combination im-
muno-CTX conditioning with GO and myeloablative (MA) BuCy
followed by alloSCT in pediatric recipients with HR CD331
AML. Nine patients, median age 8 yr (0.75–17 yr) with HR
CD331 AML (1 CR3, 5 IF, 3 refractory disease) were studied. Do-
nor sources were: 1 6/6 HLA-matched sibling peripheral blood
stem cell (PBSC), 1 10/10 matched unrelated donor (MUD), 7 um-
bilical cord blood (UCB) (2 6/6, 2 5/6 and 3 4/6). Conditioning was
GO on day -14, Bu (12.8 mg/kg if age. 4 yr; 16 mg/kg if age\4 yr)
day -7 to -4 and Cy (120 mg/kg) day -3 to -2. Unrelated alloSCT
recipients received rabbit antithymocyte globulin (8 mg/kg) from
day -5 to -2. GO was given as a dose escalation; 3 patients each re-
ceived 3 mg/m2, 4.5 mg/m2 and 6 mg/m2. All patients received
enoxaparin (1 mg/kg) from day -15 to 121 as prophylaxis for sinu-
soidal obstruction syndrome (SOS). There has been no GO dose
limiting toxicity to date. Mean neutrophil and platelet engraftment
in all patients was on day 24 6 10 (n5 8) and day 546 49 (n5 7),respectively. In the UCB group, mean neutrophil and platelet en-
graftment was on day 28 6 8 (n 5 6) and day 64 6 56 (n 5 5), re-
spectively. Mean donor chimerism on days 30 and 60 was 96%65
and 96%610, respectively. One patient (GO dose 4.5 mg/m2) de-
veloped mild SOS on day 33 that resolved without therapy. One pa-
tient died of extensive chronic graft vs. host disease on day 269 and 4
of progressive disease (day. 200), while 4 are surviving recurrence-
free at a median of 52 months. Combination immuno-CTX condi-
tioning with GO and MA BuCy followed by AlloSCT has been well
tolerated to date in children with HR CD331 AML and resulted in
$95% donor chimerism. The maximal tolerated dose (MTD) of
GO as part of a preparative regimen for MA alloSCT in children
with CD331 AML has yet to be determined. We are currently ac-
cruing patients at the next dose level of GO (7.5 mg/m2).203
UNRELATED DONOR UMBILICAL CORD BLOOD TRANSPLANT FOR HE-
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Familial Hemophagocytic Lymphohistiocytosis (HLH) is a rare
disorder of immunoregulation that is usually fatal if untreated.
Characterized by fever, hepatosplenomagaly, CNS disease, coagu-
lation disorders, pancytopenia and hemaophagocytosis, onset is
usually prior to age 1. Stem cell transplant (SCT) is the only curative
option, however, most children lack suitable matched related do-
nors. Umbilical cord blood (UCB) is banked and rapidly available,
and it has a lower incidence of acute and chronic GVHD and less
viral contamination when compared with adult stem cell sources.
HLH is a disease of infants, so UCB cell dose is not a limiting factor.
All of these features make UCB an attractive stem cell source for
transplantation in this patient population, however there are few re-
ports of UCBT for HLH. Here we report the results of 10 children
treated at Duke University Medical Center and the University of
Florida with HLH who underwent unrelated donor UCBT be-
tween 1994 and 2007. Seven girls and 3 boys received their
UCBT at a median of 6 months of age, with all but one having
well controlled disease prior to transplant. Treatment prior to
UCBT was with VP-16, cyclosporine, and decadron. The prepara-
tive regimen consisted of busulfan (Bu), cyclophosphamide (Cy)/
Etoposide (VP-16)/antithymocyte globulin (ATG) in the 4 most re-
cent patients, and Bu/Cy/ATG in 6. All children successfully
achieved neutrophil engraftment at a median of 17 (range 13–26)
days. The median time to platelets greater than 50,000 was 53
days, and PRBC independence was 41 days. Four children experi-
enced grade I, 1 grade II, 1 grade III and 1 Grade IV acute
GVHD, while the remainder had none. All children with grade
II-IV GVHD received steroids and the child with grade IV
GVHD also received daclizumab. Other complications included
veno-occlusive disease (VOD) in 4 children, and infections. Eight
of 10 children (80%) are surviving event free for a median of 7 years
post transplant. One died at day1 30 of hepatic failure attributed to
VOD and GVHD, the other at day1 72 of pulmonary hemorrhage,
CMV and Parainfluenza pneumonia. Survival following SCT for
HLH is reported in many series at 50–60%. VOD, organ damage
and GVHD are significant contributors to morbidity and mortality.
In combination with initial HLH treatment, UCBT with a standard
myeloablative, chemotherapy-based preparative regimen appears
promising, providing an 80% event free survival in this pilot patient
population.204
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